These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 31571928)
1. Treatment Response To Osimertinib In Li H; Yu T; Huang M; Guo A; Qian X; Yin Z Onco Targets Ther; 2019; 12():7785-7790. PubMed ID: 31571928 [TBL] [Abstract][Full Text] [Related]
2. Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports. Li G; Fang M; Zhou Y; Liu X; Tian P; Mei F Heliyon; 2023 Oct; 9(10):e20690. PubMed ID: 37860534 [TBL] [Abstract][Full Text] [Related]
3. Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC. Zheng MM; Li YS; Tu HY; Jiang BY; Yang JJ; Zhou Q; Xu CR; Yang XR; Wu YL J Thorac Oncol; 2021 Feb; 16(2):250-258. PubMed ID: 33122107 [TBL] [Abstract][Full Text] [Related]
4. Osimertinib Combined with Systemic Chemotherapy for EGFR Mutant, T790M-Negative, Non-Small Cell Lung Cancer Patients Who Develop Leptomeningeal Metastases with Extracranial Progression to Prior EGFR TKI. Kim HR; Jo H; Kim H; Hong J; Park S; Jung HA; Lee SH; Ahn JS; Ahn MJ Cancer Res Treat; 2023 Jan; 55(1):344-349. PubMed ID: 35344648 [TBL] [Abstract][Full Text] [Related]
5. Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status. Xu H; Chen H; Kong J; Zhang Y; Liu S; Yang G; Yang L; Wang Y Ann Transl Med; 2021 Jun; 9(11):937. PubMed ID: 34350252 [TBL] [Abstract][Full Text] [Related]
6. Osimertinib Improves Overall Survival in Patients with Leptomeningeal Metastases Associated with Zhang M; Ma W; Liu H; Jiang Y; Qin L; Li W; Zhang J Evid Based Complement Alternat Med; 2021; 2021():6968194. PubMed ID: 34457028 [TBL] [Abstract][Full Text] [Related]
7. Treatment response to osimertinib in a patient with leptomeningeal metastasis from lung adenocarcinoma following failure of gefitinib and erlotinib: A case report. Li J; Liu X; Yuan C Mol Clin Oncol; 2018 Sep; 9(3):321-324. PubMed ID: 30112177 [TBL] [Abstract][Full Text] [Related]
8. Standard dose osimertinib for erlotinib refractory T790M-negative Arulananda S; Do H; Rivalland G; Loh Z; Musafer A; Lau E; Mitchell P; Dobrovic A; John T J Thorac Dis; 2019 May; 11(5):1756-1764. PubMed ID: 31285867 [TBL] [Abstract][Full Text] [Related]
9. Non-small cell lung cancer leptomeningeal metastases treated with intrathecal therapy plus osimertinib and temozolomide and whole-brain radiation therapy: a case report. Wang Y; Liu S; Wei X; Yan B; Li J; Su Z; Liu A; Zhang Y Onco Targets Ther; 2018; 11():4733-4738. PubMed ID: 30127621 [TBL] [Abstract][Full Text] [Related]
10. Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysiss. Bian DJH; Lazaratos AM; Maritan SM; Quaiattini A; Zeng Z; Zhu Z; Sener U; Malani R; Kim YJ; Ichihara E; Cohen V; Rose AAN; Bouganim N; Dankner M Heliyon; 2024 May; 10(9):e29668. PubMed ID: 38698967 [TBL] [Abstract][Full Text] [Related]
11. Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR. Sakai H; Hayashi H; Iwasa T; Hasegawa Y; Takeda M; Nakagawa K ESMO Open; 2017; 2(Suppl 1):e000104. PubMed ID: 28848674 [TBL] [Abstract][Full Text] [Related]
12. Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. Tan CS; Cho BC; Soo RA Lung Cancer; 2016 Mar; 93():59-68. PubMed ID: 26898616 [TBL] [Abstract][Full Text] [Related]
13. Activity of EGFR Tyrosine Kinase Inhibitors in NSCLC With Refractory Leptomeningeal Metastases. Flippot R; Biondani P; Auclin E; Xiao D; Hendriks L; Le Rhun E; Leduc C; Beau-Faller M; Gervais R; Remon J; Adam J; Planchard D; Lavaud P; Naltet C; Caramella C; Le Pechoux C; Lacroix L; Gazzah A; Mezquita L; Besse B J Thorac Oncol; 2019 Aug; 14(8):1400-1407. PubMed ID: 31108248 [TBL] [Abstract][Full Text] [Related]
14. Molecularly targeted therapies in non-small cell lung cancer: The evolving role of tyrosine kinase inhibitors. Doval DC; Desai CJ; Sahoo TP Indian J Cancer; 2019 Nov; 56(Supplement):S23-S30. PubMed ID: 31793439 [TBL] [Abstract][Full Text] [Related]
15. Osimertinib administration via nasogastric tube in an EGFR-T790M-positive patient with leptomeningeal metastases. Takeda T; Itano H; Takeuchi M; Nishimi Y; Saitoh M; Takeda S Respirol Case Rep; 2017 Jul; 5(4):e00241. PubMed ID: 28469919 [TBL] [Abstract][Full Text] [Related]
16. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. Jiang T; Su C; Ren S; Cappuzzo F; Rocco G; Palmer JD; van Zandwijk N; Blackhall F; Le X; Pennell NA; Zhou C; J Thorac Dis; 2018 Jul; 10(7):3909-3921. PubMed ID: 30174832 [TBL] [Abstract][Full Text] [Related]
17. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report. Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356 [TBL] [Abstract][Full Text] [Related]
18. Case report: Rechallenge with EGFR-TKIs after immunotherapy in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis. Qian C; Zhang Y; Cheng W; Zhang Q; Li M; Fang S Front Oncol; 2022; 12():957661. PubMed ID: 36457498 [TBL] [Abstract][Full Text] [Related]
19. Management of CNS metastases in patients with EGFR mutation-positive NSCLC. Shetty V; Babu S Indian J Cancer; 2019 Nov; 56(Supplement):S31-S37. PubMed ID: 31793440 [TBL] [Abstract][Full Text] [Related]
20. Can we define the optimal sequence of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of epidermal growth factor receptor-mutant nonsmall cell lung cancer? Sun JM; Park K Curr Opin Oncol; 2017 Mar; 29(2):89-96. PubMed ID: 28085680 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]